SUPN Supernus Pharmaceuticals Inc

NASDAQ
$42.66

Supernus Pharmaceuticals Inc (SUPN) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is $0.66 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.4% since its last earnings release on August 3, 2026.

Supernus Pharmaceuticals Beat Consensus Estimates, Raises Guidance, but Remains In-line with Estimates
Monday, August 3, 2026 · 6:35 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 6:35 AM ET
Earnings Whisper
-
vs $0.66
Rev est $223.67M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $44.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc., is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 8 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.